Jeff P. | Authors


ELEVATE-TN Shows Acalabrutinib Is Well-Tolerated in CLL

December 17, 2019

Jeff P. Sharman, MD, discusses the safety profile of acalabrutinib that was demonstrated in the phase III ELEVATE-TN trial. The trial evaluated acalabrutinib as a single agent or in combination with obinutuzumab versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.